WO2007030145A3 - Elastin protective polyphenolics and methods of using the same - Google Patents

Elastin protective polyphenolics and methods of using the same Download PDF

Info

Publication number
WO2007030145A3
WO2007030145A3 PCT/US2006/012027 US2006012027W WO2007030145A3 WO 2007030145 A3 WO2007030145 A3 WO 2007030145A3 US 2006012027 W US2006012027 W US 2006012027W WO 2007030145 A3 WO2007030145 A3 WO 2007030145A3
Authority
WO
WIPO (PCT)
Prior art keywords
elastic fibers
tannic acid
acid
methods
ellagic acid
Prior art date
Application number
PCT/US2006/012027
Other languages
French (fr)
Other versions
WO2007030145A2 (en
Inventor
Felipe Jimenez
Thomas Mitts
Aleksander Hinek
Original Assignee
Human Matrix Sciences Llc
Hospital For Sick Children
Felipe Jimenez
Thomas Mitts
Aleksander Hinek
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Matrix Sciences Llc, Hospital For Sick Children, Felipe Jimenez, Thomas Mitts, Aleksander Hinek filed Critical Human Matrix Sciences Llc
Priority to CA2603102A priority Critical patent/CA2603102C/en
Priority to EP06824685A priority patent/EP1874340A4/en
Publication of WO2007030145A2 publication Critical patent/WO2007030145A2/en
Publication of WO2007030145A3 publication Critical patent/WO2007030145A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/39—Heterocyclic compounds having sulfur as a ring hetero atom having oxygen in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/602—Glycosides, e.g. rutin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/645—Proteins of vegetable origin; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)

Abstract

Dermal fibroblasts permanently loose their ability to synthesize elastin, the major component of elastic fibers, shortly after puberty. This progressive loss of elastic fibers cannot be replaced, resulting in the physical signs of aging. The present invention provides methods and compositions containing the polyphenols ellagic acid and/or tannic acid for protection against degradation of cutaneous elastic fibers by the elastolytic enzymes. The use of ellagic acid and/or tannic acid increased the overall deposition of elastic fibers in healthy and damaged skin cells. The protection of both intra- tropoelastin and extra-cellular mature elastic fibers from proteolytic enzymes by ellagic acid and tannic acid caused an increase in the net deposition of elastic fibers. Therefore, embodiments of the present invention provide methods and composition for the treatment of skin and prevention and treatment of degradation of dermal elastic fibers.
PCT/US2006/012027 2005-03-29 2006-03-29 Elastin protective polyphenolics and methods of using the same WO2007030145A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA2603102A CA2603102C (en) 2005-03-29 2006-03-29 Elastin protective polyphenolics and methods of using the same
EP06824685A EP1874340A4 (en) 2005-03-29 2006-03-29 Elastin protective polyphenolics and methods of using the same

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US66596605P 2005-03-29 2005-03-29
US60/665,966 2005-03-29
US75882106P 2006-01-13 2006-01-13
US60/758,821 2006-01-13

Publications (2)

Publication Number Publication Date
WO2007030145A2 WO2007030145A2 (en) 2007-03-15
WO2007030145A3 true WO2007030145A3 (en) 2009-04-16

Family

ID=37836298

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/012027 WO2007030145A2 (en) 2005-03-29 2006-03-29 Elastin protective polyphenolics and methods of using the same

Country Status (3)

Country Link
EP (1) EP1874340A4 (en)
CA (1) CA2603102C (en)
WO (1) WO2007030145A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8114829B2 (en) 2005-02-22 2012-02-14 Human Matrix Sciences, Llc Elastin protective polyphenolics and methods of using the same
US8642578B2 (en) 2005-03-29 2014-02-04 Human Matrix Sciences, Llc Elastin protective polyphenolics and methods of using the same

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63313707A (en) * 1987-06-16 1988-12-21 Seven Kagaku:Kk Skin cosmetic
JPH07138142A (en) * 1993-10-15 1995-05-30 Noevir Co Ltd Skin external preparation
JP2001072571A (en) * 1999-09-08 2001-03-21 Noevir Co Ltd Skin preparation for external use
EP1145709A1 (en) * 2000-04-14 2001-10-17 Laboratoires Serobiologiques Use of natural products to prepare cosmetic compositions
JP2002205913A (en) * 2001-01-10 2002-07-23 Ichimaru Pharcos Co Ltd Cosmetic composition
JP2003128511A (en) * 2001-10-18 2003-05-08 Ichimaru Pharcos Co Ltd Agent for preventing aging of skin
WO2004047620A2 (en) * 2002-11-26 2004-06-10 Clemson University Fixation method for bioprostheses
JP2006160685A (en) * 2004-12-09 2006-06-22 Jc Community:Kk Oral agent for preventing or ameliorating skin aging
EP1284133B1 (en) * 2001-08-18 2006-10-11 Cognis IP Management GmbH Mixtures of active agents
US20060264375A1 (en) * 2005-02-22 2006-11-23 Felipe Jimenez Elastin protective polyphenolics and methods of using the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2611140B1 (en) * 1987-02-20 1991-02-22 Lamaison Jean Louis PROCESS FOR OBTAINING TANNIC PRINCIPLES OF PLANT ORIGIN, COSMETOLOGICAL COMPOSITION AND PHARMACEUTICAL COMPOSITION CONTAINING THE PURIFIED TANNIC PRINCIPLE OBTAINED ACCORDING TO THE PROCESS
FR2768927B1 (en) * 1997-10-01 2000-01-21 Lvmh Rech USE OF ELLAGIC ACID, ITS SALTS, ITS METAL COMPLEXES, ITS MONO- OR POLY-ETHERS, MONO- OR POLY-ACYL DERIVATIVES IN THE FIELD OF COSMETICS AND PHARMACY, ESPECIALLY DERMATOLOGY
AU4229200A (en) * 1999-04-22 2000-11-10 Howard Murad Methods and compositions for treating dermatological disorders with fruit extracts
US20020127256A1 (en) * 2001-03-01 2002-09-12 Howard Murad Compositions and methods for treating dermatological disorders
WO2004073616A2 (en) * 2003-02-14 2004-09-02 Human Matrix Sciences Llc Elastin digest compositions and methods utilizing same
FR2854897B1 (en) * 2003-05-12 2007-05-04 Sederma Sa COSMETIC OR DERMOPHARMACEUTICAL COMPOSITIONS FOR REDUCING THE SIGNS OF SKIN AGING.
CA2568360A1 (en) * 2004-05-28 2005-12-15 Human Matrix Sciences, Llc Prognostic tests for development of dermal stretch marks and implications for the preventive treatment thereof

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63313707A (en) * 1987-06-16 1988-12-21 Seven Kagaku:Kk Skin cosmetic
JPH07138142A (en) * 1993-10-15 1995-05-30 Noevir Co Ltd Skin external preparation
JP2001072571A (en) * 1999-09-08 2001-03-21 Noevir Co Ltd Skin preparation for external use
EP1145709A1 (en) * 2000-04-14 2001-10-17 Laboratoires Serobiologiques Use of natural products to prepare cosmetic compositions
JP2002205913A (en) * 2001-01-10 2002-07-23 Ichimaru Pharcos Co Ltd Cosmetic composition
EP1284133B1 (en) * 2001-08-18 2006-10-11 Cognis IP Management GmbH Mixtures of active agents
JP2003128511A (en) * 2001-10-18 2003-05-08 Ichimaru Pharcos Co Ltd Agent for preventing aging of skin
WO2004047620A2 (en) * 2002-11-26 2004-06-10 Clemson University Fixation method for bioprostheses
JP2006160685A (en) * 2004-12-09 2006-06-22 Jc Community:Kk Oral agent for preventing or ameliorating skin aging
US20060264375A1 (en) * 2005-02-22 2006-11-23 Felipe Jimenez Elastin protective polyphenolics and methods of using the same

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
DATABASE CA [online] "false", XP008118681, Database accession no. 2006:600956 *
DATABASE CA [online] "false", XP008118682, Database accession no. 2004:349205 *
DATABASE CA [online] "false", XP008118683, Database accession no. 2003:130600 *
DATABASE CA [online] "false", XP008118684, Database accession no. 2002:547219 *
DATABASE CA [online] "false", XP008118685, Database accession no. 2001:194759 *
DATABASE CA [online] "false", XP008118686, Database accession no. 2001:759572 *
DATABASE CA [online] "false", XP008118687, Database accession no. 1995:92918 *
DATABASE CA [online] "false", XP008118688, Database accession no. 1989:160250 *
ISENBURG J. C. ET AL.: "Tannic acid treatment enhances biostability and reduces calcification of glutaraldehyde fixed aortic wall", BIOMATERIALS, vol. 26, 2005, pages 1237 - 1245, XP025280361 *
See also references of EP1874340A4 *

Also Published As

Publication number Publication date
WO2007030145A2 (en) 2007-03-15
CA2603102A1 (en) 2007-03-15
EP1874340A2 (en) 2008-01-09
EP1874340A4 (en) 2010-06-30
CA2603102C (en) 2015-08-11

Similar Documents

Publication Publication Date Title
DK1768500T3 (en) Compositions suitable for treating cutaneous signs of aging
WO2009065857A3 (en) Compositions for reducing oxidative stress and uses thereof
WO2010056675A3 (en) Antioxidant compositions for the cleansing and conditioning of skin
WO2011053783A3 (en) Ax213 and ax132 pcsk9 antagonists and variants
WO2010039538A3 (en) Flavivirus inhibitors and methods for their use
WO2008063382A3 (en) Antagonists of pcsk9
WO2008057458A3 (en) Antagonists of pcsk9
WO2008133647A3 (en) Antagonists of pcsk9
MX342293B (en) Bioactive compositions from theacea.
EP2662088A3 (en) Anti-connexin compounds and uses thereof
WO2006105359A3 (en) Methods for stimulating hair growth by administering bmps
WO2004089407A3 (en) Zwitterionic immunomodulators for the treatment of asthma and allergy
WO2009098698A3 (en) Compartmental extract compositions for tissue engineering
MX2010003019A (en) Adherent cells from adipose or placenta tissues and use thereof in therapy.
WO2005119899A3 (en) Use of lacritin in promoting ocular cell survival
EP3330252A3 (en) Isoprenyl compounds and methods thereof
WO2009079451A3 (en) Compositions and methods of promoting wound healing
WO2008017025A3 (en) Combination therapy
WO2006018454A3 (en) Cosmetic preparation comprising hyaluronic acid and saponins for treatment of skin aging phenomena
WO2006135493A3 (en) A composition for wound healing and use thereof
WO2007074456A3 (en) Inhibition of cxcr4 and/or cell motility by phenylalanine, cysteine or peptides containing said aminoacids
WO2004064719A3 (en) Synergistic compositions and methods for potentiating anti-oxidative activity
WO2007030145A3 (en) Elastin protective polyphenolics and methods of using the same
WO2007015175A3 (en) Use of pp-1 inhibitors to prevent missplicing events
UA94231C2 (en) Oligonucleotides or their functional homologues, a composition comprising the same and a method of treating b cell neoplasm

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2603102

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006824685

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: RU